Type 2 Diabetes: Uses of thiazolidinediones and insulin
نویسندگان
چکیده
منابع مشابه
Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achieving adequate glycaemic control is an important aim of therapy. Thiazolidinediones, or glitazones, have been used for the treatment of diabetes for a decade. Rosiglitazone and pioglitazone are currently available, however recent concerns around cardiovascular safety have led to restrictions on their...
متن کاملEffectiveness and side effects of thiazolidinediones for type 2 diabetes.
OBJECTIVE To assess effectiveness and side effects of thiazolidinediones (TZDs) as adjunctive therapy in suboptimally controlled patients with type 2 diabetes. DESIGN AND SETTING Review of a prospectively recorded database at the Royal Melbourne Hospital diabetes clinic. PARTICIPANTS 203 patients with type 2 diabetes who received pioglitazone or rosiglitazone between 1 May 2000 and 31 Octob...
متن کاملMechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.
Whereas thiazolidinediones (TZDs) are known to rapidly improve insulin action in animals, short durations of TZD therapy have never been studied in humans. Among the many known actions of TZDs, increased circulating levels of the high molecular weight (HMW) multimer of adiponectin may be an important insulin-sensitizing mechanism. We examined the effects of only 21 days of 45 mg of pioglitazone...
متن کاملShort Insulin Tolerance Test Can Determine the Effects of Thiazolidinediones Treatment in Type 2 Diabetes
PURPOSE The short insulin tolerance test is a simple and reliable method of estimating insulin sensitivity. This study was designed to compare the insulin sensitizing effects of thiazolidinediones (TZDs) on the degree of insulin resistance, determined by a short insulin tolerance test (Kitt) in type 2 diabetic patients. PATIENTS AND METHODS Eighty-three subjects (mean age = 57.87 +/- 10.78) w...
متن کاملThiazolidinediones and blood lipids in type 2 diabetes.
We evaluated study population characteristics and treatment effects on blood lipids between studies in which either rosiglitazone (RSG) or pioglitazone (PIO) was investigated in patients with type 2 diabetes. We performed a summary analysis of all published double-blind, placebo-controlled studies with RSG (4 and 8 mg/d) and PIO (15, 30, and 45 mg/d). Data were analyzed by the random-effects mo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Care
سال: 2011
ISSN: 0149-5992,1935-5548
DOI: 10.2337/dc10-2235